Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabalumab + Bortezomib + Dexamethasone in Previously Treated Multiple Myeloma
NCT01602224Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2012
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of tabalumab in multiple myeloma (MM), sponsored by Eli Lilly and Company. Started Jul 2012; status: completed.
02
Drugs
tabalumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01602224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01602224.